secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0000950170-23-000576
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics completes GLP-tox study for SAB-142 T1D therapeutic; IND filing within 12 months
--------------------------------------------------------------------------------

- SAB-142 well tolerated in GLP-tox study; dose-dependent pharmacologic effect confirmed.
- First fully-human anti-thymocyte hpAB for type 1 diabetes; may avoid immune reactions seen with animal-derived antibodies.
- SAB to submit IND filing within approximately 12 months.
- SAB-142 dosed at 1, 5, and 10 mg/kg; prolonged lymphodepletion suggests potential for optimized dosing.
- Potential to delay onset/progression of type 1 diabetes and other T-cell mediated autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023000576/0000950170-23-000576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023000576/sabs-20230110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer